Immatics (IMTX) Expected to Announce Earnings on Thursday

Immatics (NASDAQ:IMTX) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 7:00 AM ET.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. The company had revenue of $23.00 million during the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Stock Performance

Shares of IMTX opened at $9.68 on Thursday. Immatics has a one year low of $3.30 and a one year high of $12.41. The stock’s fifty day moving average is $9.84 and its 200-day moving average is $9.44. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -5.26 and a beta of 1.34.

Institutional Investors Weigh In On Immatics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL bought a new stake in shares of Immatics in the 4th quarter worth approximately $575,000. The Manufacturers Life Insurance Company boosted its holdings in Immatics by 18.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 55,300 shares of the company’s stock worth $557,000 after buying an additional 8,500 shares in the last quarter. Jump Financial LLC acquired a new position in Immatics in the fourth quarter worth approximately $534,000. Vanguard Personalized Indexing Management LLC grew its position in Immatics by 3.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock worth $518,000 after buying an additional 1,739 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Immatics by 105.2% in the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock valued at $420,000 after buying an additional 40,058 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IMTX. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Immatics in a research report on Monday, November 24th. Mizuho set a $25.00 price target on shares of Immatics in a research report on Thursday, February 19th. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research note on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Finally, Leerink Partners reiterated an “outperform” rating and set a $17.00 price objective on shares of Immatics in a research note on Thursday, December 4th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Immatics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.